Computational design of short-chain dehydrogenase Gox2181 for altered coenzyme specificity.

J Biotechnol

State Key Laboratory of Bioreactor Engineering, New World Institute of Biotechnology, East China University of Science and Technology, Shanghai 200237, PR China.

Published: September 2013

Short-chain dehydrogenase Gox2181 from Gluconobacter oxydans catalyzes the reduction of 2,3-pentanedione by using NADH as the physiological electron donor. To realize its synthetic biological application for coenzyme recycling use, computational design and site-directed mutagenesis have been used to engineer Gox2181 to utilize not only NADH but also NADPH as the electron donor. Single and double mutations at residues Q20 and D43 were made in a recombinant expression system that corresponded to Gox2181-D43Q and Gox2181-Q20R&D43Q, respectively. The design of mutant Q20R not only resolved the hydrogen bond interaction and electrostatic interaction between R and 2'-phosphate of NADPH, but also could enhance the binding with 2'-phophated of NADPH by combining with D43Q. Molecular dynamics simulation has been carried out to testify the hydrogen bond interactions between mutation sites and 2'-phosphate of NADPH. Steady-state turnover measurement results indicated that Gox2181-D43Q could use both NADH and NADPH as its coenzyme, and so could Gox2181-Q20R&D43Q. Meanwhile, compared to the wild-type enzyme, Gox2181-D43Q exhibited dramatically reduced enzymatic activity while Gox2181-Q20R&D43Q successfully retained the majority of enzymatic activity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2013.07.029DOI Listing

Publication Analysis

Top Keywords

computational design
8
short-chain dehydrogenase
8
dehydrogenase gox2181
8
electron donor
8
nadh nadph
8
hydrogen bond
8
2'-phosphate nadph
8
enzymatic activity
8
nadph
5
design short-chain
4

Similar Publications

Background: The TREAT-AD centers aim to improve Alzheimer's Disease (AD) research by offering free, high-quality tools and technologies. Lyn is a tyrosine kinase that belongs to the Src family kinases. The expression of Lyn and its activity have been implicated in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Certara SimCyp, Berwyn, PA, USA.

Background: While a number of recent anti-amyloid antibodies demonstrated a robust reduction of amyloid biomarkers in clinical trials, the impact on functional improvement is much more variable. We hypothesize that this larger variability is driven by comedications, common genotype variants and underlying tau pathology.

Method: In a previously calibrated computational neuroscience model of ADAS-Cog, we implemented the effect of soluble amyloid monomers and oligomers on glutamate and nicotinic AChR neurotransmission and the effect of intracellular tau oligomers on voltage-gated Na and K+ channels and synaptic density.

View Article and Find Full Text PDF

Cezanne-2 (Cez2) is a deubiquitinylating (DUB) enzyme involved in the regulation of ubiquitin-driven cellular signaling and selectively targets Lys11-linked polyubiquitin chains. As a representative member of the ovarian tumor (OTU) subfamily DUBs, it performs cysteine proteolytic isopeptide bond cleavage; however, its exact catalytic mechanism is not yet resolved. In this work, we used different computational approaches to get molecular insights into the Cezanne-2 catalytic mechanism.

View Article and Find Full Text PDF

Background: The use of technology in elderly population has increased in the past years due to COVID-19. Therefore it is relevant to identify the factors that contribute and limit the effective use of technology by older people. In particular, digital skills have shown to be relevant to determine the attitude toward the use of technology and consequently to have an effect on usage behavior.

View Article and Find Full Text PDF

Background: Annual cognitive screening in older adults is essential for early detection of cognitive impairment, yet less than half of cases are detected in primary care. We introduce two innovative app-based screeners that help overcome barriers to routine cognitive screening. MyCog is a tablet app that is self-administered in person during the rooming process for a primary care visit (Figure 1).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!